ClearLax label centers on short-term osmotic relief for occasional constipation
ClearLax contains polyethylene glycol 3350 at 17 g per dose and is labeled as an osmotic laxative for relief of occasional constipation, or irregularity. The product is positioned for once-daily use in adults and children 17 years and older, with a typical response expected in 1 to 3 days. In practical terms, the drug works by retaining water in the intestinal lumen, softening stool and increasing stool volume enough to stimulate evacuation without the stimulant effect seen with other laxatives.
The label is straightforward about its intended role. This is not a chronic bowel regimen packaged as a daily habit; it is a short-term agent for temporary constipation, and the instructions explicitly limit use to no more than 7 days unless a clinician directs otherwise. For patients who have simple, infrequent constipation, that distinction is clinically important because prolonged self-treatment can delay evaluation of underlying obstruction, medication effects, metabolic disease, or colonic dysfunction.
One sentence captures the central safety message: persistent constipation is not the same as a minor nuisance when it is accompanied by abdominal pain, nausea, or a change in bowel habits.
Renal caution, abdominal symptoms, and when self-treatment should stop
The warning section draws a firm line around kidney disease. People with kidney disease are told not to use the product except under a physician’s advice and supervision. Although polyethylene glycol 3350 is minimally absorbed, the label still treats renal disease as a setting that warrants clinical oversight, reflecting concern about fluid shifts, dehydration risk, or the broader fragility of patients who may already have altered electrolyte handling.
The label also advises patients to ask a doctor before use if they have nausea, vomiting, abdominal pain, a sudden change in bowel habits lasting more than 2 weeks, or irritable bowel syndrome. Those are not casual exclusions. Nausea and abdominal pain can signal obstruction, inflammatory disease, or a surgical abdomen, while a sustained change in bowel habits may point to pathology that should not be masked by over-the-counter laxative use. Irritable bowel syndrome adds another layer of complexity because symptoms may overlap with constipation-predominant disease, yet the management strategy often needs to be tailored rather than improvised.
If rectal bleeding develops, or if nausea, bloating, cramping, or abdominal pain worsens, the label instructs users to stop and seek medical advice. Diarrhea is also a stop signal. Loose watery stool is an expected pharmacologic effect of an osmotic laxative, but frank diarrhea can overshoot the therapeutic goal and leave patients dehydrated or weak, especially older adults or those with limited oral intake.
How the dose is measured and why dissolution matters
Directions for use are precise. Adults and children 17 years and older are instructed to use the product once daily, filling the bottle cap to the top of the white section marked for the correct 17 g dose. The powder is then stirred and dissolved in 4 to 8 ounces of beverage at cold, hot, or room temperature before drinking. Full dissolution is required, and the label says not to drink it if clumps remain.
Those details matter because osmotic laxatives depend on even dispersion to deliver a predictable effect. Clumping can make dosing erratic and may also create a poor palatability experience that discourages adherence. The product should not be combined with starch-based thickeners used for difficulty swallowing, a warning that reflects potential incompatibility in patients who use thickened liquids for dysphagia. In that setting, mixing laxatives into thickened preparations could alter viscosity or compromise safe swallowing practices.
Children 16 years and younger are directed to ask a doctor before use. Pediatric constipation has a different differential diagnosis and a different treatment threshold, and a label for an adult-dose OTC laxative appropriately avoids broad self-directed use in younger patients.
Adverse effects are predictable, but duration limits matter
The expected on-treatment effect is loose, watery, more frequent stool. That is the mechanism of action expressed at the bedside. The same water-retaining property that softens stool can produce diarrhea if the dose is excessive or the bowel is more responsive than anticipated. The label’s one-week ceiling is therefore more than a regulatory line; it is a safeguard against masking persistent disease and against prolonged exposure when a patient has not actually solved the underlying cause of constipation.
Patients are also told to consult a pharmacist or doctor before use if they are taking a prescription drug. This caution does not specify a single interaction, but it reflects a common medication-safety principle: constipation is often secondary to other therapies, and polypharmacy makes it easy to overlook contributors such as anticholinergics, opioids, iron products, or antihypertensive regimens. A patient who keeps reaching for an OTC laxative may need a medication review rather than another dose.
Pregnant or breast-feeding patients are told to ask a health professional before use. Even when systemic absorption is low, the label keeps the recommendation conservative, which is standard for nonprescription products that are often chosen without direct clinical supervision.
Packaged as a generic OTC product with familiar labeling signals
ClearLax is listed as a HUMAN OTC DRUG LABEL with Abbreviated New Drug Application status. The active ingredient is polyethylene glycol 3350, and the product is packaged in bottle sizes of 238 g, 510 g, and 850 g. The principal display panel describes it as unflavored, grit-free, sugar-free, and once-daily. It also states that the product is comparable to MiraLAX’s active ingredient, signaling a generic formulation meant to deliver the same therapeutic class effect.
The packaging instructions include standard tamper-evident language: do not use the product if the printed foil seal under the cap is missing, open, or broken. Storage is listed at 68°–77°F. A poison control number is provided for overdose situations, which is routine for OTC products but still a meaningful reminder that even familiar laxatives can be misused.
For clinicians, the label is notable less for novelty than for discipline. It reinforces the narrow lane where polyethylene glycol 3350 belongs: short-term relief of occasional constipation, with explicit caution around abdominal symptoms, renal disease, prolonged symptoms, and persistent need for laxatives. When those guardrails are respected, the drug remains a low-complexity option. When they are ignored, a simple constipation complaint can become the first missed clue to something more serious.